PD 0348292 + Enoxaparin

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Venous Thrombosis

Conditions

Venous Thrombosis

Trial Timeline

Mar 1, 2006 → Jul 1, 2007

NCT ID

NCT00306254

About PD 0348292 + Enoxaparin

PD 0348292 + Enoxaparin is a phase 2 stage product being developed by Pfizer for Venous Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00306254. Target conditions include Venous Thrombosis.

What happened to similar drugs?

6 of 20 similar drugs in Venous Thrombosis were approved

Approved (6) Terminated (2) Active (13)

✅Dalteparin (Fragmin) + Unfractionated heparinPfizerApproved

✅Apixaban + Standard of CarePfizerApproved

✅ApixabanBristol Myers SquibbApproved

✅enoxaparin sodiumSanofiApproved

✅enoxaparinSanofiApproved

✅Long DOAC + Short DOACBayerApproved

🔄Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00306254	Phase 2	Completed	Mar 1, 2006	Jul 1, 2007	Venous Thrombosis

Competing Products

20 competing products in Venous Thrombosis

See all competitors

Product	Company	Stage	Hype Score
Edoxaban	Daiichi Sankyo	Pre-clinical	26
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)	Daiichi Sankyo	Phase 2	35
Edoxaban + Dalteparin + Low molecular weight heparin	Daiichi Sankyo	Phase 3	40
Edoxaban	Daiichi Sankyo	Pre-clinical	26
Edoxaban + Standard of Care	Daiichi Sankyo	Phase 3	40
DU-176b + DU-176b + DU-176b + DU-176b + Placebo	Daiichi Sankyo	Phase 2	35
15mg DU-176b + 30mg DU-176b + Fondaparinux	Daiichi Sankyo	Phase 3	40
DU-176b (edoxaban) + Enoxaparin sodium 20mg	Daiichi Sankyo	Phase 3	40
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	40
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarin	Daiichi Sankyo	Phase 3	40
YM150	Astellas Pharma	Phase 3	40
YM150	Astellas Pharma	Phase 3	40
YM150 + enoxaparin	Astellas Pharma	Phase 2/3	38
YM150 + Placebo + Enoxaparin	Astellas Pharma	Phase 2/3	38
YM150	Astellas Pharma	Phase 3	40
YM150	Astellas Pharma	Phase 3	40
YM150 + Placebo + Enoxaparin	Astellas Pharma	Phase 2/3	38
Dalteparin sodium + Dalteparin sodium/aspirin	Eisai	Pre-clinical	26
dalteparin injection	Eisai	Phase 3	32
ONO-7684 + ONO-7684 Placebo	Ono Pharmaceutical	Phase 1	29